These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31314201)

  • 1. Is Ustekinumab the best treatment option in patients with Crohn's disease and coexistent multiple sclerosis?
    Kapizioni C; Makris K; Kourkoulis P; Vrakas S; Michalopoulos G
    Acta Gastroenterol Belg; 2019; 82(2):337. PubMed ID: 31314201
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ustekinumab for the treatment of Crohn's disease -Indication of Ustekinumab according to efficacy and safety].
    Ishihara S; Kawashima K; Kinoshita Y
    Nihon Shokakibyo Gakkai Zasshi; 2019; 116(3):216-223. PubMed ID: 30853674
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease.
    Huff-Hardy K; Bedair M; Vazquez R; Burstein E
    Inflamm Bowel Dis; 2017 Oct; 23(10):E49. PubMed ID: 28858074
    [No Abstract]   [Full Text] [Related]  

  • 4. Ustekinumab in a patient with pyoderma gangrenosum and refractory Crohn's disease.
    García Cámara P; Zubiri Ara ML; García López S
    Med Clin (Barc); 2019 Oct; 153(8):e35-e36. PubMed ID: 30795905
    [No Abstract]   [Full Text] [Related]  

  • 5. Ustekinumab as Effective Treatment for Refractory Amicrobial Pustulosis of the Folds Associated with Crohn's Disease.
    Al-Raddadi R; Frances C; Moguelet P; Bachmeyer C; Guégan S
    Acta Derm Venereol; 2017 Mar; 97(3):389-390. PubMed ID: 27722763
    [No Abstract]   [Full Text] [Related]  

  • 6. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study.
    de Risi-Pugliese T; Seksik P; Bouaziz JD; Chasset F; Moguelet P; Gornet JM; Bourrier A; Amiot A; Beaugerie L; Francès C; Guégan S;
    J Am Acad Dermatol; 2019 Mar; 80(3):781-784. PubMed ID: 30003991
    [No Abstract]   [Full Text] [Related]  

  • 7. Metastatic Cutaneous Crohn's Disease of the Face-A Case Successfully Treated With Ustekinumab.
    Martins Figueiredo L; Oliveira AM; Martins A
    J Crohns Colitis; 2020 Jul; 14(6):874-875. PubMed ID: 31630151
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient.
    Assefa GT; Kaneko S; Oguro H; Morita E
    J Dermatol; 2019 Mar; 46(3):e112-e113. PubMed ID: 30151838
    [No Abstract]   [Full Text] [Related]  

  • 9. Refractory Pyoderma Gangrenosum in a Patient With Crohn's Disease: Complete Response to Ustekinumab.
    Nunes G; Patita M; Fernandes V
    J Crohns Colitis; 2019 May; 13(6):812-813. PubMed ID: 30535292
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful Treatment With Ustekinumab for Enterocutaneous Fistulas in Crohn's Disease.
    Madarame A; Kimura H; Kunisaki R
    J Crohns Colitis; 2020 May; 14(4):569-570. PubMed ID: 31616911
    [No Abstract]   [Full Text] [Related]  

  • 11. Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn's Disease.
    Chateau T; Angioi K; Peyrin-Biroulet L
    J Crohns Colitis; 2020 May; 14(4):571. PubMed ID: 31606743
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab (Stelara) for Crohn's disease.
    Med Lett Drugs Ther; 2017 Jan; 59(1511):5-6. PubMed ID: 28026835
    [No Abstract]   [Full Text] [Related]  

  • 14. Ustekinumab-Induced Remission of Two Cases of Refractory Cutaneous Crohn's Disease.
    Patel BM; Ramos Rivers C; Koutroumpakis F; Ahsan M; Dueker J; Hashash J; Johnston E; Barrie A; Harrison J; Schwartz M; Babichenko D; Tang G; Binion D
    Inflamm Bowel Dis; 2021 Oct; 27(10):e124. PubMed ID: 33999193
    [No Abstract]   [Full Text] [Related]  

  • 15. Ustekinumab to treat Crohn's disease.
    Gisbert JP; Chaparro M
    Gastroenterol Hepatol; 2017 Dec; 40(10):688-698. PubMed ID: 29042094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab: a novel therapeutic option in Crohn's disease.
    Simon EG; Samuel S; Ghosh S; Moran GW
    Expert Opin Biol Ther; 2016 Aug; 16(8):1065-74. PubMed ID: 27341173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent.
    Bertrand V; El Haite A; Carré D
    Pediatr Dermatol; 2017 Jul; 34(4):e214-e215. PubMed ID: 28436109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease.
    Huang X; Li X
    Clin Gastroenterol Hepatol; 2022 May; 20(5):e1216. PubMed ID: 33991689
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Multicenter, Prospective Study in China.
    Cao Q; Chen C; Gao X; Chen Y; Hu N; Liang J; Wu K
    Inflamm Bowel Dis; 2022 Jun; 28(Suppl 2):S42-S44. PubMed ID: 35442448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease.
    Van den Berghe N; Verstockt B; Vermeire S; Thomas D; Declerck P
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):838-840.e2. PubMed ID: 34942369
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.